Home - Silexion
Silexion Technology is a platform technology consisting of siRNA and PLG microparticle product for the treatment of solid tumors. Second generation, SIL-204 is designed to inhibit KRAS …
science - Silexion
Silexion Therapeutics combines cutting-edge science, advanced technologies, and a passion for innovation to address the significant unmet medical needs in pancreatic cancer treatment.
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid …
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid …
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid …
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid …
Publication - Silexion
Prior to joining Silexion, from January 2021 to December 2022, Ms. Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd. (currently, Nasdaq: GAUZ), a …
Silexion Therapeutics Presented the LODER™ phase 2 summary …
Jan 16, 2025 · About 90% of pancreatic cancer patients have a mutagenic KRAS mutation and Silexion’s product is directed to about 75% of the KRAS mutations for this cancer population. …
Oct 22, 2024 · extraordinary general meeting online by visiting https://www.cstproxy.com/ silexion/2024 or by calling 1 800-450-7155 (toll-free, within the U.S. and Canada) or +1 857 …
Silexion’s siRNA platform technology is designed to silence oncogenes and prevent the production of the mutated KRAS proteins that drive cancer growth. Loder siRNA with an …